Basal Cell Nevus Syndrome (BCNS) Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working | Delveinsight

Gorlin-Goltz syndrome, also known as Basal Cell Nevus Syndrome, is a multisystemic autosomal dominant condition with high penetrance and varied expression (Online Mendelian Inheritance in Man, MIM, 109400). Basal cell cancers and epidermal cysts of the skin, calcified dural folds, keatocysts of the jaws, palmar and plantar pits, ovarian fibromas,harcteri medulloblastomas, lymphomesentreic cysts, foetal rhabdomyomas, and various maldevelopmental stigmata characterize the basal cell nevus syndrome (BCNS) (e.g., rib and vertebral abnormalities, cleft lip or cleft palate, and cortical defects of bones)

DelveInsight’s “Basal Cell Nevus Syndrome (BCNS) Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Basal Cell Nevus Syndrome (BCNS), historical and forecasted epidemiology as well as the Basal Cell Nevus Syndrome (BCNS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

Some of the key facts of the Basal Cell Nevus Syndrome (BCNS) Market Report:

  • The prevalence of the BCNS is approximate to be 1 among the population of 56,000-164,000 people

  • Children younger than 20 years of age are more prone to this disease

  • The Disease affects all type of genders equally with a ratio of 1:1

  • In the United States, around 1 million cases of the Basal Cell Nevus Syndrome (BCNS) are diagnosed each year

Request a sample for the Report: https://www.delveinsight.com/sample-request/basal-cell-nevus-syndrome-market

Basal Cell Nevus Syndrome (BCNS) Symptoms: 

The primary symptoms of the BCNS include- 

  • Skin Pits on the hand & Feet

  • Abnormal Deposit of calcium in the brain

  • Abnormalities in the Bones of the spine, & Ribs

  • Large head size

  • Abnormal tissue growth

  • Noncancerous tumors of the heart

  • Noncancerous tumors of the ovary 

Basal Cell Nevus Syndrome (BCNS) Market: 

The dynamics of the Basal Cell Nevus Syndrome (BCNS) market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as and others during the forecasted period 2022-2032. 

The market size of the BCNS is growing due to the advanced clinical, & pharmaceutical research the key leading companies in the field are- UCSF Benioff Children's Hospital Oakland, PellePharm, Inc., Palvella Therapeutics, Inc., Novartis Pharmaceuticals, Case Comprehensive Cancer Center, UCSF Benioff Children's Hospital Oakland. 

Learn more by requesting for sample @Basal Cell Nevus Syndrome (BCNS) Market Landscape  

Basal Cell Nevus Syndrome (BCNS) Pipeline Therapies and Key Companies: 

  • GDC-0449

  • Patidegib Topical Gel, 2%

  • Vismodegib

  • PTX-022

  • LDE225

  • Dietary Vitamin D3 pre-treatment

Basal Cell Nevus Syndrome (BCNS Key Companies:

  • UCSF Benioff Children's Hospital Oakland

  • PellePharm, Inc.

  • Palvella Therapeutics, Inc.

  • Novartis Pharmaceuticals

  • Case Comprehensive Cancer Center

  • UCSF Benioff Children's Hospital Oakland 

Related Reports: 

Basal Cell Nevus Syndrome (BCNS) Pipeline  

"Basal Cell Nevus Syndrome (BCNS) Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Basal Cell Nevus Syndrome (BCNS) market. A detailed picture of the Basal Cell Nevus Syndrome (BCNS) pipeline landscape is provided, which includes the disease overview and Basal Cell Nevus Syndrome (BCNS) treatment guidelines. 

Basal Cell Nevus Syndrome (BCNS) Epidemiology

DelveInsight's 'Basal Cell Nevus Syndrome (BCNS)  Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Basal Cell Nevus Syndrome (BCNS) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. 

Latest Reports by DelveInsight

Comments

Post a Comment

Popular posts from this blog

Understanding the Selectivity of CELMoDs in Targeting Cancer Cells

Image
  What is Multiple myeloma and How is it to be treated? Multiple myeloma is a cancer of plasma cells, and it affects approximately 138,000 people worldwide. The multiple myeloma market is dominated by several drugs, with REVLIMID being the leading therapy. However, with the entry of CELMoDs , such as iberdomide, many believe that they could be a worthy successor to REVLIMID. Generic competition to REVLIMID REVLIMID, also known as lenalidomide, is one of the most widely prescribed drugs for multiple myeloma . However, the drug has faced significant competition in recent years, with the entry of generic versions in 2022. The introduction of generic REVLIMID has had a considerable impact on the multiple myeloma market , with many patients switching to cheaper alternatives. The arrival of CELMODS CELMoDs, or cereblon modulating drugs, are a new class of drugs that work in a similar way to REVLIMID. They are designed to modify the activity of cereblon, a protein that plays a crucial r...
Read more

Hopeful Horizons: Advancing Multiple System Atrophy Treatment Strategies

Image
Neurodegenerative diseases like Multiple System Atrophy (MSA) pose significant challenges to patients and the medical community. However, ongoing research and promising therapeutic approaches offer hope for better management and potential treatments. In this blog, we'll explore the latest developments in MSA treatment. Neurodegenerative Connections: Similarities Between Multiple System Atrophy and Parkinson’s Disease Multiple System Atrophy shares clinical and pathological features with Parkinson's Disease (PD) . Both conditions are characterized by the accumulation of abnormal alpha-synuclein protein in the brain. Understanding these shared characteristics has led to potential crossover treatments, as advancements in PD research may benefit MSA patients. Breaking Ground: Promising Multiple System Atrophy Treatment Approaches 1. Samsara BioCapital's Investment: Samsara BioCapital's funding in MSA research has been instrumental in driving innovative treatment strategi...
Read more

The Emergence of Advanced Ocular Implant Technologies

Image
The ocular implants market is a rapidly growing industry that involves the use of medical devices to improve vision and treat eye conditions. Ocular implants are artificial devices that are placed within the eye to replace or supplement natural eye structures. In this blog, we will discuss what ocular implants are, their major benefits and drawbacks, regional market assessment, key companies in the ocular implants market, and future market assessment. What are Ocular Implants? Ocular implants are medical devices that are designed to improve vision and treat eye conditions such as cataracts , glaucoma , diabetic retinopathy , and macular degeneration. These devices are made of various materials, including silicone, acrylic, and polymethyl methacrylate (PMMA), and are surgically implanted into the eye. Ocular Implants – Major Benefits and Drawbacks The major benefits of ocular implants are improved vision and reduced dependence on glasses or contact lenses. They can also treat various ...
Read more